Pneumonia is a lung infection, where the small sir sacs known as alveoli are affected by viruses, bacteria, or fungi. The symptoms of pneumonia consist of fatigue, shortness of breath, fever, cough and cold. Streptococcus pneumoniae is the most usual bacterial kind that causes pneumonia. There are several tests that are used to detect pneumonia in an individual such as are sputum test, blood tests, pulse oximetry and chest X-ray. Certain additional tests such as Pleural fluid culture or CT scan are required for pneumonia detection if the patient is older than age 65.
Request for Analysis of COVID-19 Impact on Pneumonia Testing Market –
The blood tests are mainly used to confirm an infection and to detect the infection causing organism, but however accurate results are not expected through the blood tests. Pneumonia could also be diagnosed with the severity and location of the infection through the chest X-ray. It could also determine the germ type causing pneumonia. Pneumonia could also be detected by the pulse oximetry test by measuring the oxygen level in the blood, as pneumonia prevents enough oxygen flow through lungs into the bloodstream. Another testing method is the sputum test, where the infection is analysed and the cause of infection is determined by testing the sample of fluid taken from lungs after deep cough.
Moreover, a chest CT scan is recommended if the patient suffering from pneumonia isn’t responding as expected to obtain a more details of the lungs. The pleural fluid culture test is further carried out if the patients show serious symptoms or health conditions. In this test, a fluid sample is collected from the pleural area by putting a needle between the ribs to analyze the type of infection.
The major factors that promote the growth of the pneumonia testing market are the recent advancements such as advancement in POC (point-of-care) tests and enhanced nucleic acid detection tests in pneumonia testing systems. POC tests are very beneficial as they are easily accessible offer rapid results after testing. For instance, an extremely-effective rapid test for legionnaire at the point-of-care allowing targeted therapy is the urinary antigen.
Other factors that drive the market growth are increasing product launches and product approvals. For instance, the Food and Drug Administration (FDA) provided 510(k) clearance to bioMérieux in November 2018 for BIOFIRE FILMARRAY Pneumonia Panel that allowed diagnosis of lower respiratory tract infections. Moreover, de novo clearance was received by Curetis N.V. from the U.S. Food and Drug Administration (FDA) in April 2018 for creating awareness in the U.S. about an automated molecular diagnostic test named as Lower Respiratory Tract Infection (LRT) Application Cartridge and also Unyvero System. The system used to detect Legionella pneumoniae microorganism by simply performing rapid tests for infectious disease in an individual.
Request PDF Brochure Report –
The pneumonia testing market expected lucrative opportunities, which are provided due rise in molecular diagnostic test adoption in the countries with developing economy. The molecular diagnostics test in pneumonia testing market is growing due to increased application and benefits of biomarkers such as aiding in early detection of specific diseases in molecular diagnostic. Market Value:-
In 2016, the valuation of the global pneumonia testing market was reached up to $932 million. The market is expected to grow at a CAGR of 9.2% over a forecast period (2017-2023), estimating to reach $1,738 million by 2023.
The major players operating in the pneumonia testing market consist of Quest Diagnostics, Thermo Fisher Scientific Inc., Meridian Biosciences, Abbott Laboratories, Bio-Rad Laboratories Inc., F-Hoffmann la Roche Ltd., Becton, Dickenson and Company, bioMerieux, Hologic Inc., and Quidel.
Major players aimed to enter the pneumonia testing market by following mergers and acquisitions. For instance, Alere was acquired by Abbott in April 2017, which dominated POC testing for pneumonia testing market with its BinaxNOW RSV Card for viral pneumonia and BinaxNOW Streptococcus pneumoniae antigen card for bacterial pneumonia.
The global pneumonia testing market is geographically expanded into various segments of North America, Latin America, Middle East, Asia Pacific, Africa and Europe. In 2016, the largest share in the pneumonia testing market was accounted by North America. The growing popularity within the healthcare sector for POC tests propelled the market growth in this region. Moreover, rising development of advanced PCR-based technologies, for faster test results, also boosts the market growth.
Furthermore, European market accounted to have second largest share in pneumonia testing market. This is mainly due to the greater awareness of health issues in a geriatric population, along with advanced development in robust healthcare infrastructure.
Moreover, pneumonia testing market is expected to grow in Asia Pacific region due to its increasing government investment in research and development. Along with it several biotechnological and pharmaceutical companies aimed to expand Asian market by maximizing their R&D efforts. Asia Pacific region provides better access of clinical trials to patients at a low operational cost, which in turn foster market growth.
Reasons to Purchase this Report
Current and future of global Pneumonia Testing market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
Regions/countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players
Buy This Complete A Business Report With Flat US $2000 Off @
Pneumonia Testing Market – Taxonomy:
By Product Type:
- Point-Of-Care (POC)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Western Blot
- Polymerase Chain Reaction (PCR)
- Immunohistochemistry (IHC)
- Molecular Diagnostics
By End User
- Diagnostic Centers
- Homecare Settings
- North America
- Latin America
- Asia Pacific
- Middle East
Major Point Answered in Pneumonia Testing Market Research Study are:
What will be the progress rate of the Pneumonia Testing Market for the conjecture period, 2020-2027?
What are the prominent factors driving the Pneumonia Testing Market across different regions?
Who are the major vendors dominating the Pneumonia Testing industry and what are their winning strategies?
What will be the market scope for the estimated period?
What are the major trends shaping the expansion of the industry in the coming years?
What are the challenges faced by the Pneumonia Testing Market?
Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027